Cell-free DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature
K Jung, M Fleischhacker, A Rabien - Clinica chimica acta, 2010 - Elsevier
Circulating cell-free DNA (cfDNA) has been suggested as a cancer biomarker. Several
studies assessed the usefulness of quantitative and qualitative tumor-specific alterations of …
studies assessed the usefulness of quantitative and qualitative tumor-specific alterations of …
Methylated circulating tumor DNA in blood: power in cancer prognosis and response
K Warton, KL Mahon, G Samimi - Endocrine-related cancer, 2016 - erc.bioscientifica.com
The aim of the present study was to perform a systematic review of published studies to
provide a robust estimation of the use of procalcitonin (ProCT) as a diagnostic marker of …
provide a robust estimation of the use of procalcitonin (ProCT) as a diagnostic marker of …
[HTML][HTML] “Liquid biopsy”—ctDNA detection with great potential and challenges
M Ma, H Zhu, C Zhang, X Sun, X Gao… - Annals of translational …, 2015 - ncbi.nlm.nih.gov
Circulating tumor DNA (ctDNA) is now being extensively studied as it is a noninvasive “real-
time” biomarker that can provide diagnostic and prognostic information before, during …
time” biomarker that can provide diagnostic and prognostic information before, during …
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients
DM Marzese, H Hirose, DSB Hoon - Expert review of molecular …, 2013 - Taylor & Francis
Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non-
invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …
invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …
Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker
M Rohanizadegan - Cancer genetics, 2018 - Elsevier
Despite all the advances in diagnosis and treatment of breast cancer, a large number of
patients suffer from late diagnosis or recurrence of their disease. Current available imaging …
patients suffer from late diagnosis or recurrence of their disease. Current available imaging …
Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis
JH Lee, H Jeong, JW Choi, HE Oh, YS Kim - Medicine, 2018 - journals.lww.com
Background: Liquid biopsies using circulating tumor DNA (ctDNA) and cell-free DNA
(cfDNA) have been developed for early cancer detection and patient monitoring. To …
(cfDNA) have been developed for early cancer detection and patient monitoring. To …
DNA methylation-based biomarkers in serum of patients with breast cancer
L Van De Voorde, R Speeckaert, D Van Gestel… - … Research/Reviews in …, 2012 - Elsevier
Alterations of genetic and epigenetic features can provide important insights into the natural
history of breast cancer. Although DNA methylation analysis is a rapidly developing field, a …
history of breast cancer. Although DNA methylation analysis is a rapidly developing field, a …
Epigenetic biomarkers of breast cancer risk: across the breast cancer prevention continuum
MB Terry, JA McDonald, HC Wu, S Eng… - Novel Biomarkers in the …, 2016 - Springer
Epigenetic biomarkers, such as DNA methylation, can increase cancer risk through altering
gene expression. The Cancer Genome Atlas (TCGA) Network has demonstrated breast …
gene expression. The Cancer Genome Atlas (TCGA) Network has demonstrated breast …
Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review
TC de Ruijter, F van der Heide, KM Smits… - Breast Cancer …, 2020 - Springer
Background In patients with hormone receptor-positive breast cancer, differentiating
between patients with a low and a high risk of recurrence is an ongoing challenge. In current …
between patients with a low and a high risk of recurrence is an ongoing challenge. In current …
[HTML][HTML] Improving early breast cancer detection: focus on methylation
KPM Suijkerbuijk, PJ Van Diest, E Van der Wall - Annals of Oncology, 2011 - Elsevier
The need for additional breast cancer screening tools is indisputably high, as one may
conclude from the high rate of interval malignancies in women undergoing regular …
conclude from the high rate of interval malignancies in women undergoing regular …